Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Brana

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
CardiotoxicityI Brana, J Tabernero
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescriptionI Brana, L L Siu
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trialA D Colevas, R Bahleda, F Braiteh, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
ESMO Open|August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsE Borazanci, A M Schram, E Garralda, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
CardiotoxicityI Brana, J Tabernero
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescriptionI Brana, L L Siu
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trialA D Colevas, R Bahleda, F Braiteh, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
ESMO Open|August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsE Borazanci, A M Schram, E Garralda, et al.
Pageof 1